Clinical trials: Brain Diseases, Metabolic
Obesity
Effects of Intragastric Balloon Surgery and Sleeve Gastrectomy on Brain Function
This is a prospective, single-center, randomized, open-label, parallel-controlled clinical trial to compare the changes in brain function after intragastric balloon and sleeve gastrectomy.
- Trial name
- NCT05127213
- Testing
- Intragastric balloon system, Sleeve gastrectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs.
- Conditions
- Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract, Neuroendocrine Neoplasm of Lung, Thymic Neuroendocrine Neoplasm
- Trial name
- NCT06523582
- Where
- 3 sites in Mexico
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
Adult Growth Hormone Deficiency
The Effects of Growth Hormone Treatment Discontinuation in Adults on Metabolic Profile, Body Composition and Quality Of Life (GAMBOL Study)
Background Growth hormone (GH) is a hormone produced by the pituitary gland which sits at the base of the brain. In adults, GH plays an important role in keeping the bones and muscles healthy, and in regulating the levels of…
- Trial name
- GAMBOL (NCT05979480)
- Testing
- Dual energy X-ray absorptiometry (DXA)
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- University Hospital Birmingham
Wilson Disease
Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease
Hypothesis: The investigators postulate that patients with Wilson disease who are asymptomatic or who have been effectively treated for their symptoms and are in a maintenance phase therapy can be safely and effectively treated…
- Trial name
- NCT01472874
- Testing
- Once a day Trientine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Yale University
Stroke, Hyperglycemia
Study of Procoagulation Markers in Stroke Patients
The Insights on Selected Procoagulation Markers and Outcomes in Stroke Trial (I-SPOT): Response to Insulin Administration and Blood Glucose Control proposal is designed to accompany the Stroke Hyperglycemia Insulin Network Effort…
- Conditions
- Stroke, Hyperglycemia, Procoagulation Markers
- Trial name
- I-SPOT (NCT01811550)
- Testing
- Glycemic Control
- Where
- 38 sites in United States
- Volunteers
- 271 people
- Sponsor
- Temple University
Gaucher Disease
Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
This is an open-label expanded access trial of prGCD in patients with Gaucher disease who require enzyme replacement therapy (ERT) and who have been treated with imiglucerase but for whom the dose has been reduced or discontinued…
- Trial name
- NCT00962260
- Testing
- Plant cell expressed recombinant glucocerebrosidase (prGCD)
- Where
- 15 sites in United States, Israel
- Sponsor
- Pfizer
Fabry Disease
Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease
The study will be a randomized, double blind, placebo-controlled study of the safety and efficacy of PRX-102 in ERT naïve male patients randomized 1:1. Patient age will be 14 to 45 years.
- Trial name
- NCT02921620
- Testing
- PRX-102
- Sponsor
- Protalix
Pompe Disease
Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease
Pompe disease (also known as glycogen storage disease type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA).
- Trial name
- NCT00113035
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
- Trial name
- NCT00837824
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Depression
Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression
This is a randomized controlled study assessing the effect of pre-emptive hyperventilation on ECT seizure duration, cerebral desaturation and remission of depressive symptoms in patients with Major Depressive Disorder.
- Trial name
- NCT02924090
- Testing
- Etomidate, Ketamine, Hyperventilation
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- University of Manitoba
Parkinson Disease, GBA Gene Mutation
The GBA Multimodal Study in Parkinson's Disease
This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease.
- Conditions
- Parkinson Disease, GBA Gene Mutation, Gaucher Disease
- Trial name
- NCT04101968
- Testing
- PET scan, neuroQWERTY
- Where
- 3 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Pacific Parkinson's Research Centre
Stroke
Exercise For Sub-acute Stroke Patients in Jamaica
Chronic hemiparetic stroke is associated changes in body composition, skeletal muscle and cardiometabolic health; specific changes include paretic limb muscular atrophy, increased intramuscular fat deposition, elevated prevalence…
- Trial name
- JAMMS (NCT01392391)
- Testing
- Task Oriented Exercise Training, Stroke Care "Get with the Guidelines"
- Where
- 2 sites in United States, Jamaica
- Volunteers
- 150 people
- Sponsor
- Baltimore VA Medical Center
Gaucher Disease, Type I, Gaucher Disease, Type III
Gaucherite - A Study to Stratify Gaucher Disease
The purpose of this research is to review data already collected and to collect new data from adults and children in England with Gaucher Disease to determine clinical factors which predict severity and response to therapy of…
- Trial name
- Gaucherite (NCT03240653)
- Testing
- Stratified response to Enzyme Therapy
- Where
- 8 sites in United Kingdom
- Volunteers
- 250 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Aging, Aortic Aneurysm, Abdominal
The Intersectional Viborg Screening Program: Cost-(Effectiveness) of Screening for Diabetes and Cardiovascular Diseases
This is an intersectional and interdisciplinary screening program in Viborg Municipality, including 67 years old citizens. This observational study will estimate the cost-effectiveness of a combined screening program for the…
- Conditions
- Aging, Aortic Aneurysm, Abdominal, Hypertension, Mass Screening
- Trial name
- VISP (NCT03395509)
- Where
- Denmark
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Central Jutland Regional Hospital
Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions. MYOBLOC will be injected directly into the salivary glands.
- Trial name
- MYSTICOL (NCT01994109)
- Testing
- MYOBLOC
- Where
- 34 sites in United States, Russia and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Friedreich Ataxia, Cardiomyopathies
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults
The goal of this clinical trial is to learn how ATI-105 administered to healthy participants at works in the body at different doses and with or without food.
- Conditions
- Friedreich Ataxia, Cardiomyopathies, Central Nervous System Diseases, Neuromuscular Diseases
- Trial name
- NCT07869654
- Testing
- ATI-105
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Adjuvia Therapeutics, Inc.
Frontotemporal Dementia
An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
This is an open-label, single subject, expanded access protocol (EAP) of the LAM-002A investigational product administered orally at 125 mg BID for 52 weeks.
- Trial name
- NCT05483322
- Testing
- LAM-002A
- Sponsor
- IRulya Therapeutics Inc.
Frontotemporal Dementia
Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia
Frontotemporal lobar degeneration(FTLD) is a common cause of early-onset dementia. FTLD is characterized multiple behavioral symptoms including mental rigidity, irritability, emotional blunting, disinhibition, apathy, and…
- Trial name
- NCT00376051
- Testing
- Citalopram
- Where
- 2 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Sunnybrook Health Sciences Centre
Friedreich Ataxia
Open Trail of γIFN for Friedreich Ataxia
The investigator proposes an open label pilot study to investigate the safety and efficacy of gamma interferon (γIFN) in patients with Friedreich's Ataxia (FRDA).
- Trial name
- NCT03888664
- Testing
- gamma interferon
- Volunteers
- 12 people
- Sponsor
- IRCCS Eugenio Medea
Friedreich's Ataxia, FRDA
GABA and GSH in FRDA
The goal of this study is to obtain gamma-aminobutyric acid (GABA) and glutathione (GSH) assessment derived from magnetic resonance spectroscopy (MRS), to be used as a potential biomarker in patients with Friedreich Ataxia (FRDA)…
- Trial name
- NCT07635030
- Testing
- MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Children's Hospital of Philadelphia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.